Use of recombinant erythropoietin for the management of severe hemolytic disease of the newborn of a K0 phenotype mother.
Very few people do not express any Kell antigens on their red blood cells (K0 phenotype). They can be immunized by transfusion or pregnancy and develop antibodies against Kell system antigens. These maternal antibodies can cause severe hemolytic disease of the fetus/newborn, as a result of the suppression of erythropoiesis and hemolysis. Multiple intrauterine transfusions in the management of severe hemolytic disease have been shown to cause erythropoietic suppression as well. Recombinant erythropoietin has been successfully used in the management of late anemia of infants with Rh hemolytic disease and in 1 case of KEL1 (Kell)-associated hemolytic disease. The authors present the case of severe hemolytic disease of a newborn due to KEL5 (Ku) isoimmunization of his K0 phenotype mother. Regular intrauterine transfusions were performed to manage the severe fetal anemia (Hb 3 g/dL). A male infant was born at the 36th week of gestation having normal hemoglobin (15.8 g/dL) and developed only mild hyperbilirubinemia. On the 15th day of life, the infant's hematocrit had fallen to 27.3%, with low reticulocyte count and low erythropoietin level. The infant was managed successfully with recombinant erythropoietin.
Manoura
Antonia
A
Department of Neonatology, University of Crete, Crete, Greece.
Korakaki
Eftychia
E
Hatzidaki
Eleftheria
E
Saitakis
Emmanuel
E
Maraka
Sofia
S
Papamastoraki
Isabella
I
Matalliotakis
Emmanuel
E
Foundouli
Kaliopi
K
Giannakopoulou
Christine
C
D000328:Adult; D004899:Erythroblastosis, Fetal / Q000097:blood / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007626:Kell Blood-Group System; D008297:Male; D011247:Pregnancy; D011994:Recombinant Proteins
D006397:Hematinics; D007626:Kell Blood-Group System; D011994:Recombinant Proteins; D004921:Erythropoietin